Endocrine Cancer News
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Overtreatment more likely in younger, male, Hispanic or Asian patients, those with extensive lymph node surgery.
Elevated risk stronger in women than men; risk for non-Hodgkin lymphoma increased in patients ≤45.
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Receiving cancer treatment at a non–National Cancer Institute-designated Comprehensive Cancer Center was associated with higher drug cost, a cohort study found.
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.